A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Terminated · Phase 4 · NCT06042920
Conditions: Palmoplantar Psoriasis, Genital Psoriasis
At a glance
- Research payments reported, 2025
- $14,129
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 130
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Deucravacitinib (drug), Placebo (drug)
- Dates
- Started 2023-10-09; completion 2025-04-25
- Results posted
- Yes
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $14,129 in research payments for this study in 2025 (2 payments).
Products named: Sotyktu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Paul S. Yamauchi, M.D., PHD Dermatology · Santa Monica, CA
- Jorge A. Garcia-zuazaga, M.D. Mohs Surgery · Concord Township, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Apex Clinical Research Center, Llc $10,579
- Clinical Science Institute $3,550
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.